2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Tuesday, November 15, 2016

9:00AM-11:00AM: Abstract Number: 2525

Patient Characteristics Predicting Remission Using Intensive Treatment Strategies in Early Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2951

Patient Outcomes in Primary Angiitis of the Central Nervous System

Vasculitis - Poster III: Rarer Vasculitides

9:00AM-11:00AM: Abstract Number: 2921

Patient Participation in Patient Reported Outcome Instrument Development in Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster III

9:00AM-11:00AM: Abstract Number: 2373

Patient Preference for Display of Electronic Patient-Reported Outcomes in Osteoarthritis Clinical Trials: Wording Emphasis, Question Format, and Navigation Button Placement

Osteoarthritis – Clinical Aspects - Poster II

9:00AM-11:00AM: Abstract Number: 2649

Patient Preferences Regarding Rheumatoid Arthritis Therapies in Lebanon: Results from a National, Multicenter, Cross-Sectional Survey

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

9:00AM-11:00AM: Abstract Number: 2173

Patient Reported Disease Activity and Efficacy of Biologic Therapy in Patients with Psoriatic Arthritis. an Observational Study of 107 Patients of the Estonian Society for Rheumatology Biologic Therapy Register during 2008-2014

Epidemiology and Public Health - Poster III

9:00AM-11:00AM: Abstract Number: 2644

Patient Survey Regarding Generic and Bio-Similar Drugs

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

9:00AM-11:00AM: Abstract Number: 2530

Patient´s Motivations for Non-Persistence with Medication Impact How They Score Compliance

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2515

Patient-Reported Outcomes in Two Randomized, Controlled Trials (RCTs) in Patients with Rheumatoid Arthritis (RA) Treated with Tocilizumab (TCZ) Monotherapy Compared with Methotrexate (MTX) or Adalimumab (ADA)

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2474

Patients’ Experiences of Using a Smartphone App for Remote Monitoring of Rheumatoid Arthritis, Integrated into the Electronic Medical Record, and Its Impact on Consultations

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2239

Patterns of Abatacept Utilization in Patients with Rheumatoid Arthritis. Have the Baseline Characteristics of These Patients Changed over Time?

Health Services Research - Poster III

9:00AM-11:00AM: Abstract Number: 2476

Performance of Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) Appears to be Better Than Gold Standard Disease Assessment Score (DAS-28 CRP)

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2912

Performance of the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 in Systemic Sclerosis -Associated Interstitial Lung Disease (SSc-ILD)

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster III

9:00AM-11:00AM: Abstract Number: 2661

Performance of the Proposed ACR-EULAR Criteria for Sjogren’s Syndrome in a Prospective Multidisciplinary Diagnostic Cohort from Daily Clinical Practice

Sjögren's Syndrome - Poster II: Clinical Science

9:00AM-11:00AM: Abstract Number: 2199

Peri-Aortic Adipose Tissue Volume Is Directly Associated with Fat Accumulation in Adjacent Trunk Muscles Independent of Other Fat Depots: The Framingham Study

Epidemiology and Public Health - ARHP Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].